Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Hadaschik

Showing results (91-100 of 269) with videos related to

Pageof 27
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 7, 2017
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantationStefanie Zschäbitz, Felix Lasitschka, Boris Hadaschik, et al.
BJU International|March 18, 2011
Treatment decision-making in localized prostate cancer: why patients chose either radical prostatectomy or external beam radiation therapyAndreas Ihrig, Monika Keller, Mechthild Hartmann, et al.
Radiation Oncology (London, England)|November 9, 2014
Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013"Stephanie E Combs, Jürgen Debus, Günter Feick, et al.
World Journal of Urology|January 4, 2011
PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapyThomas Hofner, Jesco Pfitzenmaier, Adel Alrabadi, et al.
Clinical Genitourinary Cancer|January 1, 2025
Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, GermanyMadeleine J Karpinski, Kevin Claassen, Lennart Möller, et al.
Sexual Medicine|October 3, 2018
Concordance and Discordance of Sexual Identity, Sexual Experience, and Current Sexual Behavior in 45-Year-Old Men: Results From the German Male Sex-StudyVeronika E Goethe, Hannes Angerer, Andreas Dinkel, et al.
Frontiers in Immunology|April 1, 2025
Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysisÁdám Széles, András Kubik, Szilárd Váncsa, et al.
International Journal of Oncology|July 30, 2014
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review)Björn Georgi, Nina Korzeniewski, Boris Hadaschik, et al.
The International Journal of Biological Markers|May 9, 2018
Discordant prostate specific antigen test results despite WHO assay standardizationMartin Boegemann, Christian Arsov, Boris Hadaschik, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 27, 2021
Repeatability of <sup>68</sup>Ga-PSMA-HBED-CC PET/CT-Derived Total Molecular Tumor VolumeRobert Seifert, Patrick Sandach, David Kersting, et al.
Pageof 27

Showing results (91-100 of 269) with videos related to

Sort By:
Pageof 27
European Journal of Cancer (Oxford, England : 1990)|March 7, 2017
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantationStefanie Zschäbitz, Felix Lasitschka, Boris Hadaschik, et al.
BJU International|March 18, 2011
Treatment decision-making in localized prostate cancer: why patients chose either radical prostatectomy or external beam radiation therapyAndreas Ihrig, Monika Keller, Mechthild Hartmann, et al.
Radiation Oncology (London, England)|November 9, 2014
Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from "Challenges and Chances in Prostate Cancer Research Meeting 2013"Stephanie E Combs, Jürgen Debus, Günter Feick, et al.
World Journal of Urology|January 4, 2011
PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapyThomas Hofner, Jesco Pfitzenmaier, Adel Alrabadi, et al.
Clinical Genitourinary Cancer|January 1, 2025
Incidence and Survival of Patients With Prostate Cancer in North-Rhine Westphalia, GermanyMadeleine J Karpinski, Kevin Claassen, Lennart Möller, et al.
Sexual Medicine|October 3, 2018
Concordance and Discordance of Sexual Identity, Sexual Experience, and Current Sexual Behavior in 45-Year-Old Men: Results From the German Male Sex-StudyVeronika E Goethe, Hannes Angerer, Andreas Dinkel, et al.
Frontiers in Immunology|April 1, 2025
Prognostic and predictive value of pre-treatment blood-based inflammatory biomarkers in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysisÁdám Széles, András Kubik, Szilárd Váncsa, et al.
International Journal of Oncology|July 30, 2014
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review)Björn Georgi, Nina Korzeniewski, Boris Hadaschik, et al.
The International Journal of Biological Markers|May 9, 2018
Discordant prostate specific antigen test results despite WHO assay standardizationMartin Boegemann, Christian Arsov, Boris Hadaschik, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 27, 2021
Repeatability of <sup>68</sup>Ga-PSMA-HBED-CC PET/CT-Derived Total Molecular Tumor VolumeRobert Seifert, Patrick Sandach, David Kersting, et al.
Pageof 27